EKF Diagnostics and Stanbio Jointly Exhibit Expanded IVD Portfolio for First Time at AACC
Complete the form below to unlock access to ALL audio articles.
Two leading global IVD businesses will be sharing the stage for the first time at the American Association for Clinical Chemistry’s Annual Meeting and Clinical Lab Expo (AACC 2012).
EKF Diagnostics, and AACC regulars Stanbio Laboratory (Boerne, Texas), will be exhibiting the EKF Diagnostics Group’s range of IVD products, which has expanded since Stanbio became part of EKF Diagnostics in June 2011.
At booth 1631, EKF Diagnostics will be premiering to the US market the Quo-Test and Quo-Lab glycated haemoglobin (HbA1c) analyzers for near-patient measurement and monitoring of diabetes.
Quo-Test, EKF Diagnostics’s flagship analyzer, is accurate, simple to use and delivers results in less than four minutes, making it ideal for the physician’s office. These industry-leading qualities have ensured that more than 1,000 units are already in use globally.
Quo-Lab is specifically designed for developing markets, and uses the same methodology as Quo-Test within an even more compact casing. The four-step testing procedure makes it a very cost effective option for small laboratories and diabetes clinics.
Stanbio Laboratory will focus on the Stanbio Beta-Hydroxybutyrate LiquiColor® (β-HB) Reagent System, which measures the main ketone produced during ketosis.
As it provides quantitative results, unlike traditional testing methods, β-HB is changing the way hospitals manage patients displaying symptoms of diabetic ketoacidosis. The liquid-stable reagent can be used on open channel analyzers from almost twenty different manufacturers.
To highlight the use of the Beta-Hydroxybutyrate LiquiColor® Reagent System, Stanbio Laboratory and EKF Diagnostics are hosting a symposium entitled, “The value, efficacy and efficiency of Beta-Hydroxybutyrate”.
This will be presented by renowned point-of-care expert, Dr James Nichols, Professor of Pathology at Tufts University School of Medicine, Boston, and Medical Director of Clinical Chemistry for Baystate Health in Springfield, Massachusetts.
Dr Nichols will discuss the relative merits of the various methods of testing for diabetic ketoacidosis, including β-HB.
The free symposium will take place at 11.30 am on Wednesday July 18th at the Westin Bonaventure Hotel, Los Angeles (15 minutes’ walk from the LA Convention Centre).
According to Julian Baines, Group CEO, “AACC Clinical Lab Expo is the first time we have showcased the full range of in vitro diagnostic products within the EKF Diagnostics portfolio. Our experts will be on hand to show delegates how our innovative and high-quality products in clinical chemistry and near-patient testing are improving patient outcomes by providing practitioners with fast and accurate results, which in turn allow them to make critical decisions.”
